SCHEMBL2473975

SCHEMBL2473975

Cc1cc(Br)ccc1/C(N)=N/O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.42
SIGMAR1 Q99720 2/20 0.41
MAPT P10636 3/20 0.40
NPC1 O15118 3/20 0.40
LMNA P02545 1/20 0.40
GFER P55789 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
DGAT1 O75907 1/20 0.39
MPO P05164 2/20 0.37
RAB9A P51151 2/20 0.37
FLT1 P17948 1/20 0.37
FLT4 P35916 1/20 0.37
KDR P35968 1/20 0.37
POLB P06746 1/20 0.36
NOS1 P29475 1/20 0.35
RECQL P46063 1/20 0.35
PLAU P00749 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2473978 1.00 GAA (0.42) GAASIGMAR1MAPTNPC1LMNA
SCHEMBL17737955 0.80 GAA (0.44) GAAMAPTNPC1LMNAGFER
SCHEMBL8002042 0.80 GAA (0.44) GAAMAPTNPC1LMNAGFER
SCHEMBL10147435 0.80 GAA (0.44) GAAMAPTNPC1LMNAGFER
SCHEMBL31646093 0.79 DGAT1 (0.42) GAASIGMAR1MAPTNPC1KMT2A
SCHEMBL6649997 0.78 PDE10A (0.47) GAASIGMAR1MAPTLMNAGFER
SCHEMBL6707729 0.78 PLAU (0.56) GAAMAPTNPC1LMNAGFER
SCHEMBL6707731 0.78 PLAU (0.56) GAAMAPTNPC1LMNAGFER
SCHEMBL2818302 0.78 GAA (0.43) GAALMNAGFERKMT2AL3MBTL1
SCHEMBL15952024 0.77 LMNA (0.47) GAAMAPTNPC1LMNAGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
EP-2370431-A1 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE Almirall S.A. (ES) 2011-10-05 EP disclosed
WO-2010072352-A1 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2010-07-01 WO disclosed
EP-2202232-A1 1,2,4-oxadiazole derivatives and their therapeutic use Laboratorios Almirall, S.A. (ES) 2010-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE S1PR1, S1PR2, S1PR3 GAA 2890/4885SIGMAR1 96/4885MAPT 3569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.